SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift Laboratories informs about outcome of board meeting

07 Nov 2023 Evaluate
Ind-Swift Laboratories has informed that the Board of Directors of the Company in their meeting held today, 7th November, 2023, have considered and approved the Standalone and Consolidated Un-audited Financial Results of Ind-Swift Laboratories for the quarter and half year ended 30th September, 2023. These Financial Results are subject to limited review. The Limited Review Report as submitted by the Statutory Auditors is also enclosed along with the Unaudited Financial Results. The un-audited financial results of the Company will also be available on the website of the Company, www.indswiftlabs.com. The Board Meeting commenced at 01:00 PM and concluded at 03:45 PM.

The above information is a part of company’s filings submitted to BSE.

Ind-Swift Lab. Share Price

140.40 8.40 (6.36%)
20-Apr-2026 15:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.80
Dr. Reddys Lab 1234.20
Cipla 1231.35
Zydus Lifesciences 937.50
Lupin 2328.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×